FMR1 and fragile X syndrome: The diverging clinical phenotypes implicate distinct molecular mechanisms in FXTAS pathophysiology, including gain-of-function effects, distinct from FMRP loss-of-function leading to synaptic dysfunction in FXS [34–37].